Egr-1 and serum response factor are involved in growth factors- and serum-mediated induction of E2-EPF UCP expression that regulates the VHL-HIF pathway

Journal of Cellular Biochemistry

Volumn 105, Issue 4, 2008, Pages 1117-1127

  Jung, Hwa Lim ^a   Jung, Cho Rok ^a   Lee, Chan Hee ^b   Im, Dong Soo ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Chungbuk National University   (South Korea)

Author keywords

E2 EPF UCP; Egr 1; Gene expression; Growth factors; HIF 1 ; SRF; VHL

Indexed keywords

E2 EPF UBIQUITIN CARRIER PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; SCATTER FACTOR; SERUM RESPONSE FACTOR; UBIQUITIN CONJUGATING ENZYME E2; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CHROMATIN IMMUNOPRECIPITATION; DNA BINDING; GEL MOBILITY SHIFT ASSAY; GENE DELETION; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UBIQUITINATION;

CELL PROLIFERATION; EARLY GROWTH RESPONSE PROTEIN 1; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; PROTEIN STABILITY; SERUM; SERUM RESPONSE FACTOR; TRANSCRIPTIONAL ACTIVATION; UBIQUITIN-CONJUGATING ENZYMES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

MUS;

EID: 55549141560     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21914     Document Type: Article

References (44)

1. Abdulkadir SA, Qu Z, Garabedian E, Song SK, Peters TJ, Svaren J, Carbone JM, Naughton CK, Catalona WJ, Ackerman JJ, Gordon JI, Humphrey PA, Milbrandt J. 2001. Impaired prostate tumorigenesis in Egr-1 deficient mice. Nat Med 2001:101-107.
2. Bilton RL, Booker GW. 2003. The subtle side to hypoxia inducible factor (HIFα) regulation. Eur J Biochem 270:791-798.
3. Boylan JM, Gruppuso PA. 1998. Uncoupling of hepatic, epidermal growth factor-mediated mitogen-activated protein kinase activation in the fetal rat. J Biol Chem 273:3784-3790.
4. Chai J, Tarnawski AS. 2002. Serum response factor: Discovery, biochemistry, biological roles and implications for tissue injury healing. J Physiol Pharmacol 53:147-157.
5. Chen SJ, Ning H, Ishida W, Sodin-Semrl S, Takagawa S, Mori Y, Varga J. 2006. The early-immediate gene EGR-1 is induced by transforming growth factor-β and mediates stimulation of collagen gene expression. J Biol Chem 281:21183-21197.
6. Cui MZ, Parry GC, Oeth P, Larson H, Smith M, Huang RP, Adamson ED, Mackman N. 1996. Transcriptional regulation of the tissue factor gene in human epithelial cells is mediated by Sp1 and Egr-1. J Biol Chem 271:2731-2739.
7. Fahmy RG, Dass CR, Sun L-Q, Chesterman CN, Khachigian LM. 2003. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 9:1026-1032.
8. Gaggioli C, Deckert M, Robert G, Abbe P, Batoz M, Ehrengruber MU, Ortonne JP, Ballotti R, Tartare-Deckert S. 2004. HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. Oncogene 24:1423-1433.
9. 2 sensing. Science 292:464-468.
10. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, Klausner RD. 1999. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 96:12436-12441.
11. 2-regulated prolyl hydroxylation. Science 202:468-472.
12. Jung CR, Hwang K-S, Yoo J, Cho W-K, Kim JM, Kim WH, Im D-S. 2006. E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med 12:809-816.
13. Kaelin WG, Jr. 2002. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673-682.
14. Khachigian LM. 2006. Early growth response-1 in cardiovascular pathobiology. Circ Res 98:186-191.
15. Khachigian LM, Williams AJ, Collins T. 1995. Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells. J Biol Chem 270:27679-27686.
16. Lee Y-S, Jang H-S, Kim J-M, Lee JS, Lee JY, Li Kim K, Shin LS, Choi JH, Jeon ES, Byun J, Kim DK. 2005. Adenoviral-mediated delivery of early growth response factor-1 gene increases tissue perfusion in a murine model of hindlimb ischemia. Mol Ther 12:328-336.
17. Liu L, Tsai JC, Aird WC. 2000. The Egr-1 gene is induced by the systemic administration of the vascular endothelial growth factor and epidermal growth factor. Blood 96:1772-1781.
18. Liu Z, Haas AL, Diaz LA, Conrad GH, Giudice J. 1996. Characterization of a novel keratinocyte ubiquitin carrier protein. J Biol Chem 271:2817-2822.
19. Lo L-W, Cheng J-J, Chiu J-J, Wung BS, Liu YC, Wang DL. 2001. Endothelial exposure to hypoxia induces Egr-1 expression involving PKCalpha-mediated Ras/Raf-1/ERK1/2 pathway. J Cell Physiol 188:304-312.
20. Malakooti J, Sandoval R, Amin MR, Clark J, Dudeja PK, Ramaswamy K. 2006. Transcriptional stimulation of the human NHE3 promoter activity by PMA: PKC independence and involvement of the transcription factor EGR-1. Biochem J 396:327-336.
21. Mitchell A, Dass CR, Sun LQ, Khachigian LM. 2004. Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumor growth by DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids Res 32:3065-3069.
22. Moorehead RA, Hojilla CV, De Belle I, Wood GA, Fata JE, Adamson ED, Watson KL, Edwards DR, Khokha R. 2003. Insulin-like growth factor-II regulates PTEN expression in the mammary gland. J Biol Chem 278:50422-50427.
23. Nutt JE, Foster PA, Mellon JK, Lunec J. 2007. hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours. Br J Cancer 96:762-768.
24. Park MY, Kim KR, Park HS, Park BH, Choi HN, Jang KY, Chung MJ, Kang MJ, Lee DG, Moon WS. 2007. Expression of the serum response factor in hepatocellular carcinoma: Implication for epithelial-mesenchymal transition. Int J Oncol 31:1309-1315.
25. Pickart CM. 2001. Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503-533.
26. Psichari E, Balmain A, Plows D, Zoumpourlis V, Pintzas A. 2002. High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signaling. J Biol Chem 277:29490-29495.
27. Pugh CW, Ratcliffe PI. 2003. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 9:677-684.
28. Riggs PK, Rho O, DiGiovanni J. 2000. Alteration of Egr-1 mRNA during multistage carcinogenesis in mouse skin. Mol Carcinog 27:247-251.
29. Rivera VM, Miranti CK, Misra RP, Ginty DD, Chen RH, Blenis J, Greenberg ME. 1993. A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity. Mol Cell Biol 13:6260-6273.
30. Ruff-Jamison S, McGlade J, Pawson T, Chen K, Cohen S. 1993. Epidermal growth factor stimulates the tyrosine phosphorylation of SHC in the mouse. J Biol Chem 268:7610-7612.
31. Safe S, Abdelrahim M. 2005. Sp transcription factor family and its role in cancer. Eur J Can 41:2438-2448.
32. Sakamoto KM, Bardeleben C, Yates KE, Raines MA, Golde DW, Gasson JC. 1991. 50 upstream sequence and genomic structure of the human primary response gene, EGR-1/TIS8. Oncogene 6:867-871.
33. Semenza GL. 2001. Hypoxia-inducible factor 1: Oxygen homeostasis and disease pathophysiology. Trends Mol Med 7:345-350.
34. Semenza GL. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732.
35. Tedesco D, Zhang J, Trinh L, Lalehzadeh G, Meisner R, Yamaguchi KD, Ruderman DL, Dinter H, Zajchowski DA. 2007. The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition. Neoplasia 9:601-613.
36. Thiel G, Cibelli G. 2002. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193:287-292.
37. Treisman R. 1986. Identification of a protein-binding site that mediates transcriptional response of the c-fos gene to serum factors. Cell 6:4305-4316.
38. Tsai JC, Liu L, Zhang J, Spokes KC, Topper JN, Aird WC. 2001. Epidermal growth factor induces Egr-1 promoter activity in hepatocytes in vitro and in vivo. Am J Physiol Gastrointest Liver Physio 281:G1271-G1278.
39. Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, Hofmann F, Deveraux QL, Hampton GM. 2004. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 23:6621-6629.
40. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. 2001. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98:1176-1181.
41. Wong WK, Ou X-M, Chen K, Shih JC. 2002. Activation of human monoamine oxidase B gene expression by a protein kinase C MAPK signal transduction pathway involves c-Jun and Egr-1. J Biol Chem 277:22222-22230.
42. Worden B, Yang XP, Lee TL, Bagain L, Yeh NT, Cohen JG, Van Waes C, Chen Z. 2005. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res 65:7071-7080.
43. Zhang P, Tchou-Wong KM, Costa M. 2007. Egr-1 mediates hypoxia-inducible transcription of the NDRG1 gene through an overlapping Egr-1/Sp1 binding site in the promoter. Cancer Res 67:9125-9133.
44. Zhong H, Mabjeesh N, Willard M, Simons J. 2002. Nuclear expression of hypoxia-inducible factor 1α protein is heterogeneous in human malignant cells under normoxic conditions. Cancer Lett 181:233-238.